Exxon Mobil downgraded, BP upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.
Top 5 Upgrades:
-
Wells Fargo upgraded BP (BP) to Overweight from Equal Weight with a price target of $57, up from $48. Wells believes commodity and trading conditions continue to pull forward BP’s $14B debt target and present capital allocation flexibility.
-
Goldman Sachs upgraded Occidental (OXY) to Buy from Neutral with a price target of $69, up from $63. The firm believes the company has a “strong outlook” for debt reduction and dividend growth potential.
-
Argus upgraded Regeneron (REGN) to Buy from Hold with an $850 price target. The recent share pullback provides an attractive entry point, the firm tells investors in a research note.
-
BTIG upgraded United Therapeutics (UTHR) to Buy from Neutral with a $728 price target. The company’s legal win against Liquidia (LQDA) “clears a path” to resumed growth through 2027, the firm says.
-
Wells Fargo upgraded Consolidated Edison (ED) to Overweight from Equal Weight with a price target of $118, up from $108. Wells views Consolidated as a “defensive diversification away from the broader AI trade.”
Top 5 Downgrades:
-
Wells Fargo downgraded Exxon Mobil (XOM) to Equal Weight from Overweight with an $182 price target. The firm sees relative valuation converging in BP’s (BP) favor, catalyzed by accelerated debt reduction and resource development.
-
Raymond James downgraded Liquidia to Outperform from Strong Buy with a price target of $53, down from $106. Liquidia’s Delaware court loss on United Therapeutics’ (UTHR) ‘327 patent removes PH-ILD from the Yutrepia/L606 model and raises uncertainty around labels, damages, and potential market restrictions, the firm tells investors in a research note. BTIG also downgraded Liquidia to Neutral from Buy,
-
UBS downgraded Ormat Technologies (ORA) to Neutral from Buy with a price target of $100, down from $157. The firm sees limited earnings upside potential through 2028 for Ormat and says the stock’s valuation multiples are generally in-line with peers.
-
JPMorgan downgraded Ethos (LIFE) to Neutral from Overweight with an unchanged price target of $37. The firm cites valuation for the downgrade.
-
JPMorgan downgraded Baldwin Group (BWIN) to Neutral from Overweight with a price target of $32, up from $30. The company agreed to be acquired by Sequence Holdings and Dell Family Office Management in a take-private transaction at $32.50 per share, the firm tells investors in a research note.
Source: finance.yahoo.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.
